| Antisense long noncoding RNAs regulate var gene activation in the malaria parasite Plasmodium falciparum I Amit-Avraham, G Pozner, S Eshar, Y Fastman, N Kolevzon, E Yavin, ... Proceedings of the National Academy of Sciences 112 (9), E982-E991, 2015 | 172 | 2015 |
| Insulator-like pairing elements regulate silencing and mutually exclusive expression in the malaria parasite Plasmodium falciparum I Avraham, J Schreier, R Dzikowski Proceedings of the National Academy of Sciences 109 (52), E3678-E3686, 2012 | 40 | 2012 |
| A nuclear redox sensor modulates gene activation and var switching in Plasmodium falciparum A Heinberg, I Amit-Avraham, V Mitesser, K Simantov, M Goyal, Y Nevo, ... Proceedings of the National Academy of Sciences 119 (33), e2201247119, 2022 | 11 | 2022 |
| Trial in progress: a phase 1-2, first-in-Human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2Rα binding … JR Vasselli, S Frentzas, AJ Weickhardt, PL de Souza, J Tang, T Wyant, ... J Clin Oncol 40 (16_suppl), 2022 | 9 | 2022 |
| 704 the computationally designed human antibody, AU-007, mediates human immune activation by endogenous IL-2, while uniquely breaking the IL-2 auto-inhibitory loop and … I Amit, I Levin, T Wyant, N Levitin, R Barak, M Ben-Mayor, O Bluvshtein, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 8 | 2021 |
| 775 Initial results from dose escalation of a phase 1/2 first-in-human, open label study of AU-007, a monoclonal antibody that binds to IL-2 and prevents its binding to CD25 … J Vasselli, P de Souza, S Frentzas, A Weickhardt, T Wyant, J Tang, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 2 | 2022 |
| Abstract C033: Preliminary pharmacodynamic evaluation of AU-007 in phase 1 dose escalation trial in patients with advanced solid tumors T Wyant, S Frentzas, E Ahern, A Weickhardt, A Haydon, J Powderly, ... Molecular Cancer Therapeutics 22 (12_Supplement), C033-C033, 2023 | 1 | 2023 |
| A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: Interim results. S Frentzas, ES Ahern, AJ Weickhardt, AM Haydon, PL de Souza, ... Journal of Clinical Oncology 41 (16_suppl), e14507-e14507, 2023 | 1 | 2023 |
| Negative Feedback Expansion of Tregs Caused by Endogenous IL-2 Limits the Activity of IL-2-based Therapies I Amit, N Levitin, M Gadrich, M Ben-Mayor, T Wyant, R Barak, L Danielpur, ... Journal of Cancer Immunology 5 (1), 29-39, 2023 | 1 | 2023 |
| 685 A phase 1/2 dose escalation and cohort expansion study of AU-007, a human monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, plus low-dose aldesleukin … M Mckean, D Rasco, A Haydon, JD Powderly, A Weickhardt, S Frentzas, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
| 464 (PB452): Determination of the phase 2 dose of AU-007, an AI-designed human monoclonal antibody that redirects IL-2 to T-effector cells T Wyant, M McKean, D Rasco, AM Haydon, JD Powderly, AJ Weickhardt, ... European Journal of Cancer 211, 114971, 2024 | | 2024 |
| Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors. DW Rasco, M McKean, AM Haydon, AJ Weickhardt, S Frentzas, ES Ahern, ... Journal of Clinical Oncology 42 (16_suppl), 2527-2527, 2024 | | 2024 |
| POS0465 A NOVEL THERAPEUTICALLY ACTIVE ANTI-TNFR2 AGONISTIC ANTIBODY PROMOTES TREG PROLIFERATION AND INDUCTION OF TREG FUNCTIONAL MARKERS T Miyazaki, M Maiti, I Amit, D Hamel, Q Wu, R Pena, K Brendza, T Chang, ... Annals of the Rheumatic Diseases 83 (Suppl 1), 1132-1132, 2024 | | 2024 |
| Engineered anti-il-2 antibodies A Inbar, I Levin, G Nimrod, S Fischman, RB FUCHS, M Strajbl, T Wyant, ... US Patent App. 18/492,028, 2024 | | 2024 |
| Engineered anti-IL-2 antibodies A Inbar, I Levin, G Nimrod, S Fischman, RB FUCHS, M Strajbl, T Wyant, ... US Patent 11,851,485, 2023 | | 2023 |
| 717 A phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors: interim results from dose … S Frentzas, E Ahern, A Weickhardt, A Haydon, J Powderly, D Rasco, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Anti-tumor necrosis factor receptor (tnfr2) antibodies and uses thereof A Inbar, I Levin, C Ayelet, V Tal, O Nino, D Samet, EC ZADA, N Levitin, ... US Patent App. 18/011,251, 2023 | | 2023 |
| Engineered anti-il-2 antibodies A Inbar, I Levin, G Nimrod, S Fischman, RB FUCHS, M Strajbl, T Wyant, ... US Patent App. 17/795,960, 2023 | | 2023 |
| Characterization of BDG8: An antibody-human IL-2 complex that selectively activates the effector arm of the immune system. T Wyant, I Amit, I Levin, N Levitan, N Grossman, O Bluvshtein, R Barak, ... Journal of Clinical Oncology 38 (15_suppl), e15004-e15004, 2020 | | 2020 |
